OncoVista Innovative Therapies, Inc. Announces the Initiation of Clinical Development of AdnaGen's Breast Cancer Circulating Tumor Cells (CTCs) Diagnostic Technology in Women with High-Risk Locally Advanced Breast Cancer
SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies, Inc. (“OncoVista”) (OTC BB: OVIT.OB) and AdnaGen Ag announced that The University of Texas M. D. Anderson Cancer Center will collaborate on clinical studies of AdnaGen’s molecular based CTC technology in Women with High-Risk Locally Advanced Breast Cancer (LABC) that have completed Neoadjuvant and Local Therapy.